BTG (LON:BTG)‘s stock had its “underperform” rating reissued by equities researchers at Royal Bank of Canada in a research note issued on Wednesday. They currently have a GBX 510 ($6.79) price target on the stock. Royal Bank of Canada’s price target would suggest a potential downside of 5.47% from the company’s current price.
Several other research analysts have also weighed in on BTG. Peel Hunt reiterated a “hold” rating and set a GBX 640 ($8.52) price objective on shares of BTG in a report on Friday, June 15th. Numis Securities reiterated a “buy” rating on shares of BTG in a report on Friday, June 15th. Deutsche Bank reiterated a “hold” rating on shares of BTG in a report on Wednesday, June 13th. Shore Capital reiterated a “buy” rating on shares of BTG in a report on Friday, June 15th. Finally, JPMorgan Chase & Co. cut their price objective on shares of BTG from GBX 680 ($9.05) to GBX 650 ($8.65) and set a “neutral” rating on the stock in a report on Wednesday, May 16th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. BTG currently has a consensus rating of “Hold” and a consensus target price of GBX 712.14 ($9.48).
BTG traded down GBX 2.50 ($0.03), reaching GBX 539.50 ($7.18), on Wednesday, MarketBeat Ratings reports. The stock had a trading volume of 387,350 shares, compared to its average volume of 582,586. BTG has a 12-month low of GBX 559.82 ($7.45) and a 12-month high of GBX 784 ($10.44).
BTG (LON:BTG) last released its earnings results on Tuesday, May 15th. The company reported GBX 32.90 ($0.44) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of GBX 29.80 ($0.40) by GBX 3.10 ($0.04). BTG had a net margin of 15.50% and a return on equity of 10.80%.
In other news, insider Duncan Kennedy sold 2,652 shares of the stock in a transaction dated Friday, June 8th. The shares were sold at an average price of GBX 556 ($7.40), for a total transaction of £14,745.12 ($19,631.37).
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, Asia, and internationally. It operates through three segments: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.